Targeted Therapies Compared to Dacarbazine for Treatment of BRAF^V600E Metastatic Melanoma: A Cost-Effectiveness Analysis

Figure 3

Cost-effectiveness acceptability curve. This acceptability curve shows, for each drug, which percentage of 10,000 Monte Carlo iterations is cost-effective over a range of WTP thresholds.